Jaden Chang currently serves as the Founder and Chief Executive Officer at ZTI Biosciences, a leading radiopharmaceutical nanoplatform company headquartered in Indiana. In this role, he oversees the company’s business operations and investment management strategies.
Prior to his current position, Jaden held a postdoctoral fellowship at the BSAC Research Center, UC Berkeley, specializing in organic semiconductors. He earned his Ph.D. in Chemical and Bio Engineering from Seoul National University, during which time he authored 33 research papers and filed for several patents. Notably, his research focused on the development of nanoparticles, which now form the cornerstone of ZTI’s technology platform. He spearheaded groundbreaking research initiatives, laying the foundation for ZTI’s pioneering work in nanoparticle-based radiopharmaceuticals.
Before he found ZTI, Jaden gained invaluable experience as a Research Senior Engineer at Samsung Display, where he honed his skills in applying scientific knowledge to large-scale nano-semiconductor technologies.
Currently, Jaden’s primary focus areas include Radiopharmaceuticals, Nano-Biotechnology, Nano medicine, Nano Engineering, Materials, Chemical Engineering, and Peptide Engineering. Under his leadership, ZTI is actively pursuing IND approval for their flagship radiopharmaceutical ZTI-201A, leveraging over 15 years of dedicated research and development.
Ashraf Dehlawi, Ph.D, is a seasoned biopharma executive with a degree in Medical Technology/Clinical Laboratory Sciences from King AbdulAziz University in Jeddah, Saudi Arabia, and a Master’s in Biotechnology and Bioinformatics coupled with a Doctorate of Business Administration in Finance from the University of South Florida in Tampa, Florida. He has extensive experience in quality management system design and implementation, product development, regulatory affairs, and clinical operations, demonstrated through leadership roles at Abbott Laboratories, Diagnostics Divisions, TuHURA Biosciences (Morphogenesis Inc.) and consultancy for SaudiVax. Dehlawi has contributed significantly to the biopharma sector, securing Orphan Drug and Fast Track and Accelerated Approval Designations for key products, and fostering international collaborations. His work supports Saudi Arabia’s Vision 2030, focusing on innovation and sustainable growth in the biopharma and diagnostics industries.
Anton Malyshev, PhD, is the founder and CEO of Lactocore, a leading-edge biotech startup focused on pioneering peptide-based medications for mental and metabolic disorders. Our breakthrough approach, powered by our proprietary computational tools, has enabled us to create a portfolio of three highly promising peptides. Our mission is to bring safe, native peptides into the fight against stress, anxiety, type 2 diabetes, and diabetic nephropathy. We believe that our experience, knowledge, and curiosity can help improve the life quality of millions across the globe.
Matthew Lorence has extensive experience in the therapeutics, genomics and molecular diagnostic industries and is currently CEO at Chimera Therapeutics, a City of Hope startup focusing on blood and autoimmune disorders. He most recently served as CEO of CDR3 Therapeutics, as President and CEO of Edge Biosystems and as SVP, Global Marketing at Calibre Scientific. His consulting experience encompasses the assessment of molecular products and services companies for acquisition by a leading life sciences private equity firm, development of a RADx-funded COVID-19 mobile testing system, and the at-home COVID-19 molecular test market opportunity, as well as serving as an external grant reviewer for Grand Challenges Canada. He earned both a PhD degree in Molecular Biology and an MBA degree in Marketing from the University of Texas at Dallas and received an NIH Postdoctoral Fellowship while in the Departments of Biochemistry and Obstetrics-Gynecology at the University of Texas Southwestern Medical Center at Dallas. Dr. Lorence has authored more than 20 peer-reviewed publications and has extensive FDA experience
Jaden Chang currently serves as the Founder and Chief Executive Officer at ZTI Biosciences, a leading radiopharmaceutical nanoplatform company headquartered in Indiana. In this role, he oversees the company’s business operations and investment management strategies.
Prior to his current position, Jaden held a postdoctoral fellowship at the BSAC Research Center, UC Berkeley, specializing in organic semiconductors. He earned his Ph.D. in Chemical and Bio-Engineering from Seoul National University, during which time he authored 33 research papers and filed for several patents. Notably, his research focused on the development of nanoparticles, which now form the cornerstone of ZTI’s technology platform. He spearheaded groundbreaking research initiatives, laying the foundation for ZTI’s pioneering work in nanoparticle-based radiopharmaceuticals.
Before he found ZTI, Jaden gained invaluable experience as a Research Senior Engineer at Samsung Display, where he honed his skills in applying scientific knowledge to large-scale nano-semiconductor technologies.
Currently, Jaden’s primary focus areas include Radiopharmaceuticals, Nano-Biotechnology, Nano medicine, Nano Engineering, Materials, Chemical Engineering, and Peptide Engineering. Under his leadership, ZTI is actively pursuing IND approval for their flagship radiopharmaceutical ZTI-201A, leveraging over 15 years of dedicated research and development.
Dr. Natalie Galant is the CEO and co-founder of Paradox Immunotherapeutics, a pharmaceutical company dedicated to the creation of antibody therapies for the treatment of rare protein misfolding diseases, especially those characterized by amyloidosis, using a platform with a proven track record of success. Prior to this role, Natalie received her PhD from the University of Toronto’s Department of Medical Biophysics, where her PhD work helped lead to the development of a monoclonal antibody currently in FDA clinical trials for the treatment of cardiac amyloidosis. She is the recipient of numerous academic fellowships, awards (incl. winner of BIO 2023 Start-Up Stadium), and has co-authored several scientific publications in research areas ranging from chemical informatics to immunotherapy drug development.
Seah is the Founder and Chief Executive Officer at Medicovestor, Inc. He brings to the company more than 25 years of leadership experience in both academia and industry. His extensive experience in drug development and the biotech industry includes being a Product Development Consultant for Bausch Health, Product Development Consultant for Genzyme, Product Development Consultant for Burroughs Wellcome & Company, and Pediatric Lead in the Global Program at Sanofi. He is currently also an Independent Director for Emmaus Medicals, Inc and Business and Scientific Advisor for Genie Therapeutics, Inc . As a practicing physician until two years ago, Seah uniquely brings to the table not only his scientific and industry knowledge and know-how but also his clinical and payor reimbursement perspectives to the company.
Seah graduated from Aberdeen University, Scotland with a commendation degree in Medicine (MB ChB), and was the most distinguished male graduand of the year. He underwent his British thesis-based MD training (mentor Professor Anthony Goldstone at University College London, London University) in cytokines and cell therapy for acute leukemias at the University College Hospital, London, and PhD training (mentors Professor Herman Waldmann at Cambridge University, and Professor Alan Burnett at Cardiff University) in antibody engineering at Cambridge University, England. He has since been Full Professor with many leadership roles (from being Program Directors to the Chief of Division) in various universities in the United Kingdom and United States, including at Brown University and University of Pittsburgh School of Medicine.
Throughout his career, Seah has been an internationally recognized translational physician scientist. He has made numerous discoveries and holds 11 patents. He is the Section Editor for Journal of Translational Medicine, and has published more than 180 manuscripts in high impact medical and scientific journals, with more than 5000 citations. He has attracted more than $18M of research grants, including numerous grants from the National Cancer Institute.
Dr. Rayees Rahman, PhD, is a co-founder and CEO of Harmonic Discovery. Dr. Rahman completed his PhD at the Icahn School of Medicine at Mount Sinai where he developed machine learning approaches to characterize the 3D structure of protein kinases and their inhibitors.
Dongxing Zha, PhD, is a seasoned drug development leader with more than two decades of experience dedicated to translating immune-oncology discoveries into innovative anti-cancer therapies. He currently serves as the Chief Technology Officer at Alloy Therapeutics. Dr. Zha co-founded and led KeywayTM TCR Discovery, where KeywayTM excels in TCRm discovery and engineering, providing discovery services to the biopharma ecosystems.
Before joining Alloy, Dr. Zha led Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson. This unique group comprised clinicians, researchers, and drug development experts collaborating to develop biologic and cell-based therapies. Under his leadership, ORBIT advanced multiple programs from the preclinical stage to clinical studies. Dr. Zha oversaw and drove the first TCRm program in clinical study for AML and MDS patients.
In addition to his role at Alloy and MD Anderson, Dr. Zha has more than a decade of experience on protein engineering in big pharma and biotech. He worked in antibody discovery and development at Merck & Co, Inc, and GlycoFi where he served as the program lead for several projects at various stages of development in oncology, autoimmune and cardiovascular diseases, and neurodegeneration. He also invented yeast display technology for antibody and glycosylation engineering. Dr. Zha obtained his Ph.D. in Molecular Biology from Huazhong Agricultural University in China and conducted his postdoctoral research on directed evolution at Max-Planck-Institut für Kohlenforschung and Novo Nordisk.
Patrik Strömberg has more than 20 years of experience from the pharmaceutical industry (AstraZeneca, Biovitrum/Sobi and AnaCardio), and has worked in leading roles in both R&D, innovation management and business development. Before joining AnaCardio as the CEO he served as Vice President, External Innovation, Search & Evaluation at Swedish Orphan Biovitrum (Sobi). He has a PhD in Biochemistry from Karolinska Institutet and also earned an MBA from Stockholm University (Stockholm Business School).